What happens when a new drug comes charging out of the launch gate? For Biogen Idec ($BIIB), it means a rethink of its real estate plans. Its fast-growing staff won't all fit in the new headquarters under construction in Cambridge, MA. Report
| December 2, 2015 | 10am ET / 7am PT | Presented By: PerkinElmer
The goals of translational R&D have placed a particular premium on the ability to rapidly collect, curate, and integrate information from a variety of sources. This presentation will discuss some of the challenges in building a sustainable technology infrastructure to support these activities, which will enable more sophisticated analytics and decision support. Reserve Your Spot Today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!